Sienna biopharmaceuticals, inc. (SNNA)
CashFlow / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-47,951

-60,775

-72,750

-73,471

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

152

155

157

157

157

145

133

120

0

0

0

Amortization of debt discount and issuance costs

0

0

0

-

-

-

-

-

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

0

0

Stock-based compensation

5,119

5,208

5,332

4,700

4,448

3,695

2,880

2,112

0

0

0

Fair value adjustment of success payment liability

-

-

-

-3,282

-5,106

-2,454

-195

2,023

0

0

0

Fair value adjustment of contingent consideration

-24,500

8,300

9,400

6,300

1,399

3,199

3,099

2,989

0

0

0

Non-cash interest expense

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

0

Loss on disposal of property and equipment

0

0

0

-

-

-

-

-

-

-

-

Impairment of operating lease – right-of-use asset

0

0

0

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Prepaid expenses and other current assets

5,279

-1,350

-874

-997

858

-910

595

1,349

0

0

0

Accounts payable and other accrued liabilities

-9,136

-7,685

-2,103

2,168

4,647

5,740

2,101

2,870

0

0

0

Net cash used in operating activities

-54,629

-52,674

-60,007

-61,693

0

0

0

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

0

Investment in property and equipment

10

26

39

39

137

217

228

274

0

0

0

Net cash used in investing activities

-10

-26

-39

-39

0

0

0

-

-

-

-

Financing activities
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of common stock, net of issuance costs, early exercise liability and repurchase of unvested early exercise stock options

21,810

26,865

26,847

5,387

5,444

371

164

188

0

0

0

Debt issuance costs related to long-term debt

-

-

0

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible promissory notes

-

-

-

-

-

-

-

3,906

0

0

0

Net cash provided by financing activities

2,171

27,164

57,404

35,960

0

0

0

-

-

-

-

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

0

Effect of exchange rate changes on cash

-143

-144

-202

-169

19

37

77

-52

0

0

0

Net decrease in cash, cash equivalents and restricted cash

-52,611

-25,680

-2,844

-25,941

-24,626

43,168

53,242

65,448

0

0

0

Supplemental Disclosure of Cash Flow Information:
Right-of-use asset obtained in exchange for lease liability

0

0

0

-

-

-

-

-

-

-

-

Warrants issued

0

0

0

-

-

-

-

-

-

-

-